The Center for Prevention of Progression of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Blood. 2019 Jun 6;133(23):2484-2494. doi: 10.1182/blood.2019846782. Epub 2019 Apr 22.
Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant plasma cell dyscrasia that consistently precedes multiple myeloma (MM) with a 1% risk of progression per year. Recent advances have improved understanding of the complex genetic and immunologic factors that permit progression from the aberrant plasma cell clone to MGUS and overt MM. Additional evidence supports bidirectional interaction of MGUS cells with surrounding cells in the bone marrow niche that regulates malignant transformation. However, there are no robust prognostic biomarkers. Herein we review the current body of literature on the biology of MGUS and provide a rationale for the improved identification of high-risk MGUS patients who may be appropriate for novel clinical interventions to prevent progression or eradicate premalignant clones prior to the development of overt MM.
意义未明的单克隆丙种球蛋白血症(MGUS)是一种癌前浆细胞增生异常,其始终先于多发性骨髓瘤(MM)发生,每年有 1%的进展风险。最近的进展提高了对允许异常浆细胞克隆进展为 MGUS 和明显 MM 的复杂遗传和免疫因素的理解。更多的证据支持 MGUS 细胞与骨髓龛中周围细胞的双向相互作用,这种相互作用调节恶性转化。然而,目前还没有强大的预后生物标志物。本文综述了目前关于 MGUS 生物学的文献,并为更好地识别高危 MGUS 患者提供了依据,这些患者可能适合新的临床干预措施,以防止进展或在明显 MM 发生之前消除癌前克隆。